Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Intel Trader who wrote (4760)	7/6/1998 4:13:00 PM
From: Steve Fancy	Read Replies (1) of 6136

Hope you're right Intel. My broker feels its likely to head for 22 1/2. Of course AGPH can see no reason for this, but they're all around if they were to open they're eyes. IMO, primary reason is adding three new uncertainties, on top of existing uncertainties, at significant cost. Now we have cut into the one sure thing the company had going for it, Viracept. I believe the investment community considers AG3340 to be another dead end, as apparently Roche did. Couple this with the selection of three new, maybe, maybe nots, and you end up with a sell off. Although the MS-DW report has me feeling a little better, stock action is pretty darn weak. Hoping for a better day tomorrow. sf

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next